An operation is the only curative treatment for PHPT. According to recent recommendations, 1 an operation is indicated in any patient younger than 50, in any symptomatic patient, and in asymptomatic patients who meet some criteria. Although a single parathyroid adenoma (single gland disease [SGD] ) is the most frequent occurrence, multiglandular disease (MGD) with multiple adenomas or multiglandular hyperplasia is present in 15-20% of cases. A conventional operation for PHPT relies on the inspection of the 4 parathyroid glands through bilateral cervical exploration. In recent years, a significant shift toward targeted operations has been proposed, relying on the accurate characterization of parathyroid glands (SGD versus MGD) by preoperative imaging.
However, first-line imaging studies show limited performance in the distinction between SGD and MGD (accuracy for predicting SGD is about 70-80%). 2 In order to further reduce the risk for operative failure, several institutions routinely use intraoperative PTH monitoring as an adjunct to determine the extent of the operation. However, intraoperative PTH monitoring does not have a consensual definition for prediction of operative cure and is still associated with the risk of unnecessary bilateral neck exploration.
Beyond a serum marker, better characterization of parathyroid tissue would be of particular interest in PHPT. Gross examination and intraoperative extemporaneous microscopic examination are unreliable. In recent years, metabolomics, or global metabolite profiling, has been used for investigating metabolite changes associated with some pathologic conditions (eg, colorectal cancers, 3 breast cancers, 4 liver cancers, 5 and pancreatic cancers 6 ). Metabolomics represents the latest stage in the multi-omics approaches and is a growing-up technique behind genomics, transcriptomics, and proteomics, generating great interest in scientific and medical communities over the past few years. Starting from a broad analysis of small molecule metabolites, the metabolomics links cellular phenotype to its genotype and provides biochemical information related to the regulation of specific gene transcripts that are altered in the tumoral genome. 7 Currently, well-recognized tools for metabolomics are nuclear magnetic resonance (NMR) spectroscopy and gas-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS). GC-MS and LC-MS are more widely represented in the technical platforms related to metabolomics, mainly because they demonstrate a better sensitivity than does NMR spectroscopy.
However, these technologies generate massive amounts of data that are often difficult to interpret or to use for building predictive models.
However, among NMR techniques, 1 H highresolution magic angle spinning (HRMAS) NMR spectroscopy is especially suited to analyzing a small volume of intact tissue samples and avoiding any chemical extraction procedures or sample manipulation, which are necessary for both MS and liquid-state NMR or well-established immunohistochemistry. HRMAS NMR spectroscopy enables identification and quantification of several metabolites from spectra with excellent resolution and signal-to-noise ratio. Recently, we and other groups have proved that metabolomics is a promising tool in the characterization of some endocrine tumors such as pheochromocytomas/ paragangliomas. 8, 9 Consequently, there is a need for accurate biomarkers that could help surgeons to distinguish between SGD and MGD. The aims of the present study were (1) to evaluate if metabolomics patterns were different between PHPT and renal hyperparathyroidism (secondary and tertiary) and (2) to compare the metabolomic profiles of SGD and MGD in PHPT patients, using metabolomics analysis.
MATERIALS AND METHODS
Patient population. Forty-three tissue samples of sporadic hyperfunctioning parathyroid tissue were analyzed and retrospectively selected from 32 patients (Fig 1) suffering from hyperparathyroidism and operated on between January 2013 and November 2014 in 2 academic endocrine tumor centers (Brabois University Hospital, Nancy, France, and La Timone University Hospital, Marseille, France). Only patients who fulfilled the following criteria were included: (1) diagnosis of hyperparathyroidism (primary versus secondary [SHPT] versus tertiary [THPT]), (2) 6-month follow-up after parathyroidectomy for PHPT in order to distinguish SGD from MGD, (3) absence of personal history of therapeutic radiation, and (4) parathyroid glands collected just after resection and snap-frozen in liquid nitrogen before storage.
A written informed consent was obtained from all the included patients. For this investigation, the tissue samples were obtained from the tumor biobank of Nancy (n8 BB-0033-00035) and Marseille University Hospitals (AP-HM tissue bank AC 2013-1786).
Disease status. For PHPT, SGD was defined when only a single abnormal gland was removed and the patient was cured (normalization of serum calcium for $6 months following parathyroidectomy). When >1 gland was involved histologically (adenoma or hyperplasia), the patient was considered to have MGD, including cases of multiple gland parathyroid hyperplasia. All patients were cured at 6 months postoperatively. Patient and tumor characteristics are detailed in Table I .
Tissue sample preparation for HRMAS NMR spectroscopy. All tissue specimens were collected during the operation just after tumor removal and were snap-frozen in liquid nitrogen until the sample preparation for the HRMAS NMR analysis. The amount of tissue used for HRMAS analysis ranged from 6-20 mg. Each tissue sample was placed in a 30 mL disposable insert. Next, 8 mL of deuterium oxide with 0.75 weight percent 2,2,3,3-D4-3-(trimethylsilyl) propionic acid were added to every biopsy's insert in order to get a chemical shift reference for the NMR spectrometer.
The exact weight of the sample used was determined by weighing the empty insert and the insert containing the tissue sample. Then, inserts were kept at À808C until the HRMAS NMR analysis was performed. The insert was stored at À808C and placed in a 4-mm ZrO 2 rotor just before the HRMAS NMR analysis. The percentage of parathyroid cells in each analyzed sample was estimated on frozen sections using a mirror sample. All examined samples contained $80% parathyroid cells.
HRMAS NMR data acquisition, spectra processing, and metabolite quantification. All HRMAS NMR spectra were achieved on an Avance spectrometer (Bruker Avance III 500; Bruker Corporation, Billerica, MA; installed in the Pathological Department of Strasbourg University Hospitals) operating at a proton frequency of 500.13 MHz and equipped with a 4-mm double resonance gradient HRMAS probe ( 1 H and 13 C). The temperature was maintained at 277.15 K throughout the acquisition time in order to reduce the effects of tissue degradation during the spectra acquisition.
A 1-dimensional (1D) proton spectrum using a Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence and 1,024 transients was acquired for each serum sample. 10 Free induction decays were multiplied by an exponential window function of 0.3 Hz prior to Fourier transformation and were corrected for phase and baseline distortions using TopSpin 3.2 (Bruker GmbH, Bremen, Germany). The chemical shift was calibrated to the peak of the methyl proton of L-lactate at 1.33 parts per million (ppm).
In order to confirm resonance assignments, 2-dimensional (2D) heteronuclear experiments were also recorded immediately after the end of the 1D spectra acquisition. Because the duration of these experiments is long and significant tissue degradation occurs during NMR acquisition, only a few representative samples were analyzed by 2D experiments. Each peak in the 2D spectra represents a correlation 1 H-
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C. Spectra were referenced by setting the lactate doublet chemical shift to 1.33 ppm in proton dimension and 22.70 ppm in carbon dimension. Metabolites were assigned using a standard metabolite chemical shift table (Table II) available in the literature. 11 HRMAS NMR data acquisition and processing have been previously detailed. 10 Metabolite quantification was performed using an external reference standard of lactate (3 mmoles), scanned under the same analytical conditions. Spectra were normalized according to sample weight. Peaks of interest were automatically defined by an in-house program using MATLAB (MATLAB 7.0; MathWorks, Natik, MA). Peak integration was then compared with the one obtained with the lactate reference and was corrected according to the number of protons. Only well-defined peaks with no overlapping in the 1D CPMG spectra were selected for quantification. Quantification results were expressed as nmol/mg of tissue.
Statistical analysis. The region between 6.54 and 2.32 ppm of each 1D HRMAS NMR spectrum was automatically bucketed into integral regions of 0.01 ppm using AMIX software (AMIX 3.9.14; Bruker GmbH) to reduce the peak shift effect due to pH variations. This procedure generated an X-data matrix with 421 columns (buckets) and 43 rows corresponding to the 43 examined samples of hyperfunctioning parathyroid tissue. In this matrix, each point represents the center of a single bucket of 0.01 ppm in the NMR spectrum. Afterward, the data set was exported and analyzed in SIMCA P (version 13.0.3; Umetrics AB, Ume a, Sweden). The detailed procedure has been previously reported by our team. 10 A combination of principal component analysis (PCA) and orthogonal partial least squaresdiscriminant analysis (OPLS-DA) was performed to analyze the data matrix. 12, 13 First, a PCA was performed to evaluate the quality of the data and to identify possible outliers. Then an OPLS-DA was employed to optimize the separation between groups and to classify the samples in each model. The following OPLS-DA models were considered: (a) PHPT versus renal HPT and (b) SGD versus MGD in PHPT. OPLS-DA was performed on the whole set of variables (spectral interval of 0.01 ppm) to select those with real discriminating power.
14 Variables corresponding to variable importance for projection (VIP) value $1 were selected, -allowing the selection of the following metabolites: fumarate, phosphorylcholine, glycerophosphocholine, choline, lactate, creatine, aspartate, GSH, glutamine, glutamate, ascorbate, succinate, b-glucose, taurine, scyllo-inositol, and myo-inositol. Cross-validation was used in each OPLS-DA model to determine the number of components and to avoid data overfitting. 15 Two measurements of model quality were reported for OPLS-DA: R 2 Y and Q 2 representing, respectively, the accuracy of fit (ie, data variation) and the accuracy of prediction, as estimated by cross-validation. Q 2 $ 0.5 can be considered a good predictor. 16 The spectra metabolic contents are directly comparable, because the intensity of each spectrum has been normalized in respect to the weight of the analyzed sample. For display purposes, the amplitude of the lactate peak at 4.09 ppm and the glycerophosphocholine at 3.21 ppm have been graphically reduced. Metabolite assignments are given in Table I . Histologic features of hyperfunctioning parathyroid glands corresponding to each spectrum are depicted at the left side of the figure (HE 3 400; scale bars, 50 mm). (Color version of this figure is available online.) and can predict the expected change's direction per metabolite, when metabolic network topology is considered. The network was constructed using Kyoto Encyclopedia of Genes and Genomes 18, 19 and Selway's work. 20 In order to compare the patients suffering from PHPT and SHPT/THPT and the patients suffering from SGD and MGD in the context of PHPT, the following groups of metabolites were defined: (1) Choline, Phosphorylcholine, Glycerophosphocholine, Total Choline; (2) Glutamine, Glutamate; (3) Glucose, Alanine, Lactate; (4) Succinate, Fumarate; (5) Glutathione, Glutamate; and (6) Glutathione, Ascorbate.
For discretization of metabolite observations, we have set a number of levels (M) as 6 and a number of levels that can be assigned to observation (k) as 4. Using the above mentioned metabolite groups and parameters, an expected metabolite level for the case and for the control is obtained per metabolite. The direction of the expected change is obtained by comparing expected levels.
RESULTS
Tissue samples. Accordingly, 19 samples were obtained from 18 patients with PHPT, 19 samples from 11 patients with SHPT, and 5 samples from 3 patients suffering from THPT. Among the 19 samples obtained from patients with PHPT, 14 were classified as SGD, while the 5 others had MGD (all were described as hyperplastic glands by the pathologist; Fig 1) . All patients were cured at 6 months postoperatively.
Spectra quality. All the spectra obtained from the 43 analyzed specimens were of high quality without any signs of tissue necrosis. The spectral region within the range of 2.32-0 ppm has been voluntarily excluded from the analysis because of important signal overlapping related to high and complex fatty acids signals. The representative 1D HRMAS NMR CPMG spectrum for each analyzed sample class is shown in Fig 2. A total of 25 metabolites were identified within the range of 6.54-2.32 ppm from the spectra obtained from all 43 tissue samples. The spectra obtained from different glands within the same patient show similar profiles.
PHPT versus renal HPT. OPLS-DA results. Fortythree samples were studied in this 2-class model. Nineteen samples were obtained from patients with PHPT and 24 from patients with renal HPT (11 patients/19 samples of SHPT and 3 patients/5 samples of THPT). PCA was first applied to our data (43 HPT), showing a homogeneous population without any outliers. The 2 classes were clearly separated by a bi-component OPLS-DA based on the VIP metabolites. (The VIP value is namely a weighted sum of squares of the PLS weights, which takes into account the explained variance of each OPLS dimension.) The VIP values were employed to identify the features contributing to group separation (Fig 3,  A) , showing an accurate representation of the data and good cumulative confidence criterion of fit (R 2 Y = 0.85) and prediction (Q 2 = 0.63). A higher level of b-glucose, ascorbate, phosphorylcholine, taurine, GSH, myo-inositol, and glutamate was revealed in patients with PHPT. On the contrary, a higher concentration of fumarate, choline, serine, glycerophosphocholine, aspartate, and glutamine was shown in patients with renal HPT.
Network analysis. When the data were analyzed using the ADEMA algorithm and the metabolic subnetwork depicted in Fig 4, a higher level of phosphorylcholine, succinate, alanine, glucose, ascorbate, GSH, and glutamate was predicted in PHPT. Moreover, a decreased level of choline, fumarate, and glutamine was predicted in PHPT. Finally, glycerophosphocholine, taurine, acetate, aspartate, valine, lactate, myo-inositol, and creatine were predicted to be equivalent between the 2 groups.
SGD versus MGD in PHPT. OPLS-DA results.
Fourteen SGD were secondly compared to 5 samples of MGD. No outliers were evident at PCA analysis. The 2nd population was homogeneous, too. A bicomponent OPLS-DA analysis based on VIP metabolites (Fig 3, B) clearly separated the 2 classes of analyzed tissues (R 2 Y = 0.96, Q 2 = 0.55), revealing a higher concentration of fumarate, b-glucose, ascorbate, myo-inositol, glycine, scyllo-inositol, and choline in SGD samples. On the other hand, SGD revealed a higher level of glutamate, glutamine, lactate, taurine, GSH, and aspartate compared with MGD.
Network analysis. Using the ADEMA algorithm, the metabolic subnetwork included a higher level of phosphorylcholine, choline, glycerophosphocholine, fumarate, succinate, lactate, glucose, glutamine, and ascorbate predicted in SGD (Fig 5) . Moreover, the model accurately predicted a decreased level of alanine, glutamate, and GSH in MGD. Finally, taurine, acetate, aspartate, valine, myo-inositol, and creatine were predicted to be equivalent between SGD and MGD.
DISCUSSION
To the best of our knowledge, this is the first study that has evaluated the metabolome of hyperfunctioning parathyroid glands in the context of parathyroid hyperfunctioning disorders. The principal conclusions that can be drawn from this preliminary study include: (1) There are differences between PHPT and renal HPT from a metabolomic standpoint. (2) SGD and MGD can be distinguished by metabolomic profiling and can be accurately predicted by our model. (3) This approach provides new insights into the relationships between metabolic pathways and parathyroid disorders.
It is widely accepted that bilateral parathyroid exploration is no longer the only option for patients with PHPT, and those with an SGD in imaging studies can also be candidates for focused approaches. Parathyroid scintigraphy (PS) and parathyroid ultrasonography (US) are the preferred approaches reported by endocrine surgeons for selecting candidates for a focused approach. 21, 22 The Positive Predictive Value for an SGD in cases of concordant results between US and PS for a single gland abnormality is about 90%. In order to reduce the risk of failure, many institutions use intraoperative PTH (IOPTH) monitoring. 23 According to the Miami criteria, 24 a 50% decrease in PTH levels 10 minutes after removal of the putative lesion suggests a curative operation. However, the assay might sometimes yield inaccurate results, [25] [26] [27] [28] as when PTH concentrations may decrease even in the presence of MGD. IOPTH monitoring might also wrongly lead to a bilateral operation. Finally, one of the main drawbacks of IOPTH is that its accuracy is widely dependent on preoperative PTH levels, gland sizes, and parathyroid tissues' sensitivity to serum calcium.
Beyond IOPTH, the use of a more specific marker tightly linked to the pathophysiology of the parathyroid disease would be of particular interest. Because HRMAS NMR spectroscopy enables rapid characterization of intact tissue, it could also be used as an intraoperative method. In our hospital, intraoperative real-time analysis is performed for gliomas in neurosurgery ("ExtempoNMR" project). Fast transportation of samples is performed by a pneumatic tube system. Sample preparation is quick and easy; it does not take more than 2 minutes to prepare snapfrozen biopsy and inclusion within an insert of a 20-mg parathyroid tissue sample. HRMAS analysis takes 10 minutes for settings and an additional 10 minutes for spectrum acquisition. Data analysis is also very quick (<10 minutes). If confirmed, this approach could be used in clinical routine for classification of SGD versus MGD and could even coexist with IOPTH. Furthermore, the cost is <$50 per sample.
Based on our preliminary results, we expect that metabolomic profiling could enable the distinction between SGD and MGD. The comparison between IOPTH and HRMAS NMR could be of particular interest in patients with concordant imaging results but also in cases of doubtful or discordant imaging findings. HRMAS NMR also provides new insights into the relationships between metabolic pathways and parathyroid disorders.
In the setting of PHPT, we have found that SGDs (all adenomas) exhibit a higher concentration of myo-inositol, scyllo-inositol, choline, phosphorylcholine, and glycerophosphocholine than hyperplastic glands. These metabolites belong to the structural components of cell membranes. 29 Myoinositol is the precursor of phosphatidylinositol, a constituent of phospholipid membranes, and is involved in cell signaling. 30 Interestingly, recent studies have shown that 18 F-fluorocholine positron emission tomography (PET) is a very promising imaging method for localization of parathyroid adenomas. [31] [32] [33] [34] [35] [36] Our results are in agreement with these observations and could represent the biologic substrate and justification to the use of 18 F-fluorocholine PET imaging in HPT. Moreover, a higher amount of succinate and fumarate was shown by network analysis within SGD compared with MGD, suggesting an increased activity of the tricarboxylic acid cycle. By contrast, MGDs exhibit a higher level of glutamate, GSH, and ascorbate, which act as antioxidants. Hyperplastic glands from PHPT also have higher levels of GSH, aspartate, and glutamate compared with those from renal HPT.
We acknowledge some limitations to the present study. First, there are a limited number of patients included in our study as well as a limited number of analyzed samples. We believe these data are preliminary and should be validated in further series. Second, patients with PHPT and MGD may have multiple adenomas in 5-7% of cases. This subset of patients is considered to be difficult to diagnose using intraoperative PTH, but this difficulty may be similar when using HRMAS NMR spectroscopy.
However, included patients with MGD did not have multiple adenomas, which might have led us to wrong conclusions about this study. Third, we acknowledge that a comparative-effectiveness study should be performed in real time to evaluate IOPTH versus HRMAS NMR spectroscopy before drawing any definitive conclusions. Lastly, this study was retrospective and may involve some bias that would have been unaccounted for.
In conclusion, the present study shows that HRMAS NMR spectroscopy provides unique and accurate information in the metabolomic classification of hyperfunctioning parathyroid glands. Furthermore, this could deepen our knowledge of hyperparathyroidism pathogenesis and may also lead to the identification of new targets for diagnosis, imaging, or future therapeutic options. Finally, if these results are confirmed in further studies, it is expected that the role of intraoperative HRMAS NMR spectroscopy could then be evaluated in the setting of PHPT.
